



## **Mr. Pierre Lemire joins the Advisory Board of QuikFlo Health Inc.**

**Calgary, Alberta, January 14, 2016 – QuikFlo Health Inc. ("QuikFlo" or the "Company") (TSXV:QF)(FRANKFURT:1QF)** is pleased to announce that Mr. Pierre Lemire, of Calgary, Alberta has joined its Advisory Board. Mr. Lemire is an accomplished executive with over 28 years of experience in the high-tech industry. He is a self-described technical evangelist with strong knowledge and experience in the commercialization of global software products. For the past 11 years, Mr. Lemire has helped drive the growth of Calgary Scientific Inc. (CSI), from a start-up to a global market leader; first as its Chief Technical Officer (CTO) and, from 2006, as President and CTO.

Mr. Lemire has developed and launched over 20 commercial software products in his career. At Calgary Scientific he created ResolutionMD, an industry-leading diagnostic medical imaging software, sold by the top OEMs in over 30 countries and approved by the FDA, Health Canada, CE Mark (Europe), CFDA (China), among others.

Previously, while CTO at Autodesk, he developed Autodesk Map which became a \$200M+ product within 3 years of its launch. He also led the engineering team for Autodesk MapGuide, an industry leading GIS product. Mr. Lemire is currently CEO of Kent Imaging, a private medical device development company in Calgary, Alberta.

Vinny Jindal, the Company's President and CEO stated: "Mr. Lemire has extensive leadership experience in healthcare and technology and an impressive toolkit in the areas of entrepreneurship, finance and business development. He is a key addition to our team and will accelerate bringing our innovative technologies to market".

Mr. Lemire was granted 100,000 incentive stock options exercisable at \$.30 for a period of 5 years pursuant to the Company's incentive stock option plan.

### **About QuikFlo**

QuikFlo Health is a medical software company developing innovative solutions for the analysis of medical images. Our primary focus is on improving outcomes for stroke patients, where

existing time delays are solvable through more efficient triage based on rapid, accurate analysis of medical images.

### **Further Information**

For further information relating to the Company or this release please visit [www.sedar.com](http://www.sedar.com), [www.quikflohealth.com](http://www.quikflohealth.com), or contact Vinny Jindal, President and CEO at 646.526.9628 or Investor Relations for the Company at 647.980.7541.

*Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*

### **Cautionary and Forward-Looking Statements**

*This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although management of the Company believes that the expectations and assumptions on which such forward looking statements and information are based are currently reasonable, actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company's ability to identify and complete suitable acquisitions to further the Company's growth, the suitability of the key members of ongoing management and the board of directors, the biomedical and technology sectors in general such as operational risks in development, research and regulatory delays or changes in plans with respect to research projects or capital expenditures; the uncertainty of the market; the uncertainty of estimates and projections relating to costs and expenses; health, safety and environmental risks; marketing and commercialization; loss of markets; competition; ability to access sufficient capital; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws, and government regulations, and other risks identified in the recent information circular available on [www.sedar.com](http://www.sedar.com). Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive and additional risks and uncertainties are set forth in the circular.*

*No undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.*